Polymer-Sirolimus-Eluting Stents in de Novo Lesions

Herz

Volumn 29, Issue 2, 2004, Pages 152-161

  Schuler, Gerhard ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Drug eluting stents; In stent restenosis; Late luminal loss; Rapamycin

Indexed keywords

ABCIXIMAB; POLYMER; RAPAMYCIN;

ARTERY DIAMETER; ARTERY INTIMA PROLIFERATION; BRAIN HEMORRHAGE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG MECHANISM; HUMAN; RESTENOSIS; REVIEW; TREATMENT OUTCOME; VASCULAR SMOOTH MUSCLE;

ADMINISTRATION, TOPICAL; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBIOTICS, ANTINEOPLASTIC; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; CORONARY STENOSIS; CORONARY VESSELS; HUMANS; POLYMERS; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STENTS;

EID: 1942455829     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-004-2569-1     Document Type: Review

References (23)

1. Degertekin M, Regar E, Tanabe K, et al. Evaluation of coronary remodeling after sirolimus-eluting stent implantation by serial three-dimensional intravascular ultrasound. Am J Cardiol 2003;91:1046-50.
2. Degertekin M, Serruys PW, Foley DP, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002;106:1610-3.
3. Farb A, Burke AP, Kolodgie FD, et al. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003;108:1701-6.
4. Foley DP, Rensing BJ, Pieper M, et al. Clinical and quantitative angiographic outcomes following elective implantation of the self-expanding Wallstent for longer coronary artery lesions-final results of the Wallstent Native Study. Int J Cardiovasc Intervent 1999;2:171-9.
5. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999;99:2164-70.
6. Gregory CR, Huie P, Shorthouse R, et al. Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury. Transplant Proc 1993;25:120-1.
7. Hamm CW, Schneider S, Senges J. Initial result of the German Drug-Eluting Stent Registry. Circulation 2003;108:Suppl:IV-533.
8. Kay IP, Ligthart JM, Virmani R, et al. The black hole: echolucent tissue observed following intracoronary radiation. Int J Cardiovasc Intervent 2003;5:137-42.
9. Kuntz RE, Baim DS. Prevention of coronary restenosis: the evolving evidence base for radiation therapy. Circulation 2000;101:2130-3.
10. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world". The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry. Circulation 2003;109:190-5.
11. Morice MC, Serruys PW, Sousa JE, et al. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. N Engl J Med 2002;346:1773-80.
12. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
13. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996;98:2277-83.
14. Regar E, Serruys PW, Bode C, et al. Angiographic findings of the multicenter randomized study with the sirolimus-eluting Bx Velocity balloon-expandable stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 2002;106:1949-56.
15. Rensing BJ, Vos J, Smits PC, et al. Coronary restenosis elimination with a sirolimus eluting stent. First European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J 2001;22:2125-30.
16. Sabate M, van der Giessen WJ, Deshpande N, et al. Late thrombotic occlusion of a malapposed stent 10 months after intracoronary brachytherapy. Int J Cardiovasc Intervent 1999;2:55-9.
17. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
18. Serruys PW, Degertekin M, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002;106:798-803.
19. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-5.
20. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-11.
21. Sousa JE, Costa MA, Sousa AGMR, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003;107:381-3.
22. Suzuki T, Kopia G, Hayashi SI, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-93.
23. Tanabe K, Gijsen FJH, Degertekin M, et al. True three-dimensional reconstructed images showing lumen enlargement after sirolimus-eluting stent implantation. Circulation 2002;106:179e-80.